Applied genetic technologies corporation.

Make remarkable happen. Beacon Therapeutics is an ophthalmic gene therapy company founded to restore and improve the vision of patients with a range of prevalent and rare …APPLIED GENETIC TECHNOLOGIES CORPORATION CONDENSED BALANCE SHEETS (Unaudited) In thousands. December 31, 2021. June 30, 2021. ASSETS. Current assets: Cash and cash equivalents $ 72,771 $ 105,052.Applied Genetic Technologies Corporation (AGTC) reported positive 3-month interim data from its ongoing phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP).Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. The company’s lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis ...

Dec 1, 2022 · GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today the successful ... Applied Genetic Technologies Corporation T: (617) 843-5728 [email protected]. Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754Apr 13, 2021 · Applied Genetic Technologies Corporation T: (617) 413-2754 [email protected] ...

Losing your Social Security Number (SSN) card can be a stressful experience. However, thanks to modern technology, applying for a replacement SSN card online has become a convenient and efficient process.Oct 24, 2022 · GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the...

Applied Genetic Technologies Corporation, a Cambridge- and Florida-based gene therapy firm better known as AGTC could go private through an acquisition by a Floridian investment firm.APPLIED GENETIC TECHNOLOGIES CORPORATION CONDENSED BALANCE SHEETS (Unaudited) In thousands. September 30, 2021. June 30, 2021. ASSETS. Current assets: Cash and cash equivalents $ 90,515 $ 105,052.Applied Genetic Technologies Corporation (AGTC) is developing a recombinant adeno-associated virus (rAAV) vector AGTC-501, also designated rAAV2tYF-GRK1-hRPGRco, to treat X-linked retinitis pigmentosa (XLRP) in patients with mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene.APPLIED GENETIC TECHNOLOGIES CORP : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in …

The Company’s filings with the SEC are available to the public from the website maintained by the SEC at www.sec.gov. Additional copies of the tender offer materials may be obtained for free by contacting Applied Genetic Technologies Corporation at 14196 NW 119 th Terrace, Suite 10, Alachua, Florida, 32165, Attention: Chief Financial Officer.

Applied Genetic Technologies Corporation 2013 Employee Stock Purchase Plan (Full titles of plans) Susan B. Washer . President and Chief Executive Officer . Applied Genetic Technologies Corporation . 14193 NW 119th Terrace, Suite 10 . Alachua, Florida 32615 (386) 462-2204

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno ...Presentation Date/Time: July 16, 2022; 3:57 PM – 4:03 PM ET. Sub-retinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa Phase 2 Randomized, Controlled, Masked Multicenter Clinical ...Dec 14, 2021 · Applied Genetic Technologies Corporation (NASDAQ: AGTC) is a Florida based clinical stage biotech concern. The company is focused on developing transformational genetic therapies for patients ... Technology has led to tractors and other vehicles that allow fewer farmers to handle much larger fields. Pesticides prevent a significant amount of crop loss due to weeds and insects, and advanced genetic engineering has led to far better c...APPLIED GENETIC TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware : 001-36370 : 59-3553710 (State or other jurisdiction. of incorporation) (Commission. File Number) (IRS Employer. Identification Number) 14193 NW 119 th Terrace . Suite 10 . Alachua, Florida, 32165

Applied Genetic Technologies Corporation T: (617) 843-5778 [email protected]. Related Quotes. Symbol Last Price Change % Change; AGTC. TRENDING. 1. Google faces antitrust fights on both US coasts ...Applied Genetic Technologies Corporation T: (617) 843-5728 [email protected]. Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. The company’s lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, …Applied Genetic Technologies Corporation is a good speculative biotech to look into. It has had a rough past, but has still been pressing on with its gene therapies, especially AGTC-501.Dec 12, 2018 · Applied Genetic Technologies Corporation announced that Biogen has terminated collaboration agreement effective as of March 8, 2019. Upon termination, the company will regain commercial rights to the...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a …Syncona Limited, a leading healthcare company focused on founding, building and funding global leaders in life science, today announces that its newly established portfolio company has agreed to acquire, by a tender offer, all outstanding shares of Applied Genetic Technologies Corporation ("AGTC") (Nasdaq: AGTC), a …

Nov 3, 2022 · Applied Genetic Technologies Corporation Contacts: IR Contact: David Carey Lazar FINN Partners T: (212) 867-1768 [email protected]. Corporate Contact: Jonathan Lieber Chief Financial ... Applied Genetic Technologies Corporation (AGTC) is developing a recombinant adeno-associated virus (rAAV) vector AGTC-501, also designated rAAV2tYF-GRK1-hRPGRco, to treat X-linked retinitis pigmentosa (XLRP) in patients with mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene.APPLIED GENETIC TECHNOLOGIES CORPORATION CONDENSED BALANCE SHEETS (Unaudited) In thousands. December 31, 2021. June 30, 2021. ASSETS. Current assets: Cash and cash equivalents $ 72,771 $ 105,052.Oct 24, 2022 · Conference Call and Webcast. Syncona and AGTC will host a conference call and webcast to review the details of the transaction on October 24, 2022 at 7:30 a.m. ET. To access the call, dial 877-407-6184 (U.S. participants) or 201-389-0877 (non-U.S. participants). A live webcast will be available in the Events and Presentations section of AGTC ... Nov 14, 2022 · GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, sent the ... Applied Genetic Technologies Corporation (AGTC) · Syncona to invest $23.3 million upfront to acquire AGTC. · AGTC to become Syncona's third retinal gene therapy company, focused on driving AGTC-501, for X-linked retinitis pigmentosa, through late-stage clinical development.Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is on the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP ...Make remarkable happen. Beacon Therapeutics is an ophthalmic gene therapy company founded to restore and improve the vision of patients with a range of prevalent and rare …Mar 30, 2022 · Applied Genetic Technologies Corp. published this content on 30 March 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 30 March 2022 18:24:09 UTC . 14 Applied Genetic Technologies reviews. A free inside look at company reviews and salaries posted anonymously by employees.

Applied Genetic Technologies Corporation May 10, 2022 at 8:00 AM · 4 min read – Facility in Alachua, Florida Is Expected to be Completed in the Fourth Quarter of 2022 –

Applied Genetic Technologies Corporation T: (617) 843-5728 [email protected]. Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754

Nov 3, 2022 · Applied Genetic Technologies Corporation Contacts: IR Contact: David Carey Lazar FINN Partners T: (212) 867-1768 [email protected]. Corporate Contact: Jonathan Lieber Chief Financial ... However, a novel new gene therapy is being developed by AGTC-501 (Applied Genetic Technologies Corporation), and recently passed the safety tests of ...GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology ...GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC ...Oct 24, 2022 · Applied Genetic Technologies Corp. is being taken private by healthcare company creator Syncona in a transaction that will keep the struggling gene therapy developer from running out of cash next year. Syncona will pay $0.34 per share, or about $23.5 million, for rights to the company, which is commonly known as AGTC. On January 11, 2022, Applied Genetic Technologies Corporation issued a press release announcing updated information regarding its ongoing X-linked retinitis pigmentosa (XLRP) clinical trials. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.Syncona to Acquire Applied Genetic Technologies Corporation. Upfront consideration in cash of $0.34 per share representing a premium of approximately 42% over AGTC’s closing stock price on ...Applied Genetic Technologies Corporation T: (617) 843-5728 [email protected]. Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754Dec 14, 2021 · Applied Genetic Technologies Corporation (NASDAQ: AGTC) is a Florida based clinical stage biotech concern. The company is focused on developing transformational genetic therapies for patients ... 12 jui. 2023 ... The new portfolio company has been created by Syncona through the combination of Applied Genetic Technologies Corporation's (AGTC's) late ...Investors. AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies with the ...A high-level overview of Applied Genetic Technologies Corporation (AGTC) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC ...GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development ...Company Type For Profit. Contact Email [email protected]. Phone Number +1 386-462-2204. Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They ...Applied Genetic Technologies Corporation T: (617) 843-5728 [email protected]. Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754Instagram:https://instagram. best mortgage companies in ncberger montague pcoracle stock news todayvwdry Applied Genetic Technologies Corporation (AGTC) reported positive 3-month interim data from its ongoing phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP). columbus financial advisorshlvx stock GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of ...Oct 24, 2022 · These now include Applied Genetic Technologies Corp., which, rather than face the “challenging” funding environment ahead, has opted for a $23.5 million sale to investment fund Syncona. AGTC ... self storage stock GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno ...Applied Genetic Technologies Corporation had $90.5 million as of September 30, 2021; enough cash to fund its operations into 2023. Read more on AGTC stock here.